Pattern of adverse drug reactions reported through VigiFlow at a tertiary care teaching hospital in North India: a retrospective analysis
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20263789Keywords:
Adverse drug reaction, Naranjo scale, Preventability, Pharmacovigilance, VigiFlow, WHO-UMC causality scaleAbstract
Background: To analyse adverse drug reactions (ADRs) reported to the VMMC & Safdarjung Hospital, New Delhi, entered into VigiFlow analysing causality, severity, preventability and outcome.
Methods: Individual case safety reports (ICSRs) entered into VigiFlow from March 2021 to March 2026 were retrospectively reviewed. Reports lacking a documented suspect drug and reaction term were excluded as incomplete. Complete reports were analysed for demographics, system organ class (SOC), suspect drug classes, causality (WHO-UMC and Naranjo scales), severity (Modified Hartwig and Siegel scale), preventability (Schumock and Thornton criteria) and outcome.
Results: Of 974 ICSRs, 925 (95.0%) were evaluable. Mean age was 38.9±17.6 years; 54.2% were male. Gastrointestinal (27.4%), skin/subcutaneous (25.1%) and general/administration-site disorders (20.1%) were most affected. Antimicrobials (24.0%), antineoplastics (13.1%) and cardiovascular drugs (11.4%) were leading suspect classes. WHO-UMC causality was probable/likely (73.4%) or possible (25.7%), with similar Naranjo findings. Reactions were mostly mild (63.4%) or moderate (29.8%); 6.8% were severe and 8 (0.9%) fatal, six linked to antineoplastic chemotherapy. Preventability was noted in 88.6%; recovery was documented in 44.6%.
Conclusions: Antimicrobials, antineoplastics and cardiovascular drugs predominated among ADRs, most being probable, mild-to-moderate and preventable. Strengthening dose monitoring, allergy screening, drug-interaction checks and ICSR completeness may reduce ADR burden, especially in oncology and radiocontrast use.
References
Jiang H, Lin Y, Ren W, Fang Z, Liu Y, Tan X, et al. Adverse drug reactions and correlations with drug-drug interactions: A retrospective study of reports from 2011 to 2020. Front Pharmacol. 2022;13:923939.
Kaufman G. Adverse drug reactions: classification, susceptibility and reporting. Nurs Stand. 2016;30(50):53-63.
Komagamine J. Prevalence of urgent hospitalizations caused by adverse drug reactions: a cross-sectional study. Sci Rep. 2024;14(1):6072.
Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;11:28595.
Hamid AA, Rahim R, Teo SP. Pharmacovigilance and its importance for primary health care professionals. Korean J Fam Med. 2022;43(5):290-5.
Kalaiselvan V, Thota P, Singh G. Pharmacovigilance Programme of India: Recent developments and future perspectives. Indian J Pharmacol. 2016;48(6):624-8.
Singh P, Verma S, Vaishnav Y, Joshi U, Agrawal M. Probing the in-depth analysis of Serious Adverse Drug Reactions in a tertiary care hospital of Central India. Explor Res Clin Soc Pharm. 2025;17:100579.
National Coordination Centre - Pharmacovigilance Programme of India (NCC-PvPI). Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India. PvPI Newsletter. 2024. Available at: https://ipc.gov.in/images. Accessed on 21 March 2026.
Uppsala Monitoring Centre. Collect your data with VigiFlow. 2025. Available at: https://who-umc.org/vigiverse/vigiflow-data-collection. Accessed on 21 April 2026
De C, Sanz EJ, De Leon J. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety. Patient Prefer Adherence. 2024;18:2261-80.
Gupta PK, Kaur J, Devi G, Chaudhary S, Maria J. The pattern of adverse drug reaction reporting at a regional pharmacovigilance center in North India: a retrospective observational study. Cureus. 2025;17(9):91812.
Yadav P, Rao GK, Rataboli PV, Gurav SS. Adverse drug reaction monitoring and reporting in a tertiary care teaching hospital in Goa. Med J DY Patil Vidyapeeth. 2025;18(3):463-72.
Vemuri VR. A retrospective and observational study of the adverse drug reactions reported in a tertiary care hospital. Int J Basic Clin Pharmacol. 2024;13(2):213-8.
Hammour KA, El-Dahiyat F, Hyari R, Salameh S, Manaseer Q, Al-Farha R, et al. A retrospective analysis of the pharmacovigilance data registry in a tertiary teaching hospital in Jordan. J Pharm Policy Pract. 2024;17(1):2378461.
Murgesh JV, Vishwanath M, Rakesh Kumar PK. A retrospective study of adverse drug reactions reported in a tertiary care hospital. National J Physiol, Pharm Pharmacol. 2023;13(11):2328-9.
The Use of the WHO-UMC System for Standardized Case Causality Assessment [Internet]. Uppsala Monitoring Centre. Available from: https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32.
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.
Lhamo Y, Purohit K, Singh S, Chopra D, Bharti M. Pattern, severity and preventability of adverse drug reactions from a Northern Indian tertiary care facility: A retrospective analysis. Int J Risk Saf Med. 2025;36(1):5-13.
Manasa MR, Karant C, Chandrasekhar BVS, Swetha K. A retrospective analysis of adverse drug reactions at a tertiary care center - patterns, causality, predictability and preventability. Pharm Biomed Res. 2025;11(3):261-70.
Selva P, Durairajan S. Exploration and evaluation of adverse drug reactions documented in a tertiary-care hospital in Chennai: an in-depth retrospective observational study. Cureus. 2024;16(5):e60977.
Keche Y, Gaikwad N, Dhaneria S. Preventability, predictability, severity and causality assessment of adverse drug reactions reported from a teaching hospital in Chhattisgarh: a retrospective analysis. J Fam Med Prim Care. 2021;10(7):2541-5.
Kumar R, Jindal A, Garg P, Kaur A, Kumar S, Tilak Raj R, et al. Pharmacovigilance study of anticancer drugs in a tertiary care teaching hospital in North India: a retrospective study. Cureus. 2023;15(9):44984.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Veena Verma, Anugya Kushwaha, Preeta Kaur Chugh, Himanshu Singh Saini
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
